Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetylcysteine plus silymarin versus N-acetylcysteine alone for drug-induced liver injury
IRCT20240720062482N1Phase 3Completed
- Sponsor
- Alborz University of Medical Sciences
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Drug-induced hepatitis (DILI) comparing Control: N-acetylcysteine with Intervention: silymarin + N-acetylcysteine (2 arms). Primary endpoints: Serum AST level, Serum ALT level and 4 more. Started Aug 2024; status: completed.
02
Drugs
silymarinacetylcysteine
03
Conditions
Drug-induced hepatitis (DILI)
Beyond the preview
Go deeper on IRCT20240720062482N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20240720062482N1.